Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tofacitinib + atorvastatin
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination of two separate medications. Tofacitinib (CP-690550) is a JAK inhibitor that primarily targets JAK1 and JAK3, interfering with the JAK-STAT signaling pathway. It is used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. Atorvastatin is a statin medication used to treat high cholesterol and triglyceride levels.
- Brand names
- Xeljanz
- Other names
- CP-690550 + atorvastatintasocitinib + atorvastatin
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)JAK3 (Janus kinase 3)JAK1 (Janus kinase 1)JAK2 (Janus kinase 2)
Beyond the preview
Go deeper on tofacitinib + atorvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tofacitinib + atorvastatin.